Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 29;29(5):1097.
doi: 10.3390/molecules29051097.

Novel Scaffold Agonists of the α2A Adrenergic Receptor Identified via Ensemble-Based Strategy

Affiliations

Novel Scaffold Agonists of the α2A Adrenergic Receptor Identified via Ensemble-Based Strategy

Shiyang Sun et al. Molecules. .

Abstract

The α2A adrenergic receptor (α2A-AR) serves as a critical molecular target for sedatives and analgesics. However, α2A-AR ligands with an imidazole ring also interact with an imidazoline receptor as well as other proteins and lead to undesirable effects, motivating us to develop more novel scaffold α2A-AR ligands. For this purpose, we employed an ensemble-based ligand discovery strategy, integrating long-term molecular dynamics (MD) simulations and virtual screening, to identify new potential α2A-AR agonists with novel scaffold. Our results showed that compounds SY-15 and SY-17 exhibited significant biological effects in the preliminary evaluation of protein kinase A (PKA) redistribution assays. They also reduced levels of intracellular cyclic adenosine monophosphate (cAMP) in a dose-dependent manner. Upon treatment of the cells with 100 μM concentrations of SY-15 and SY-17, there was a respective decrease in the intracellular cAMP levels by 63.43% and 53.83%. Subsequent computational analysis was conducted to elucidate the binding interactions of SY-15 and SY-17 with the α2A-AR. The binding free energies of SY-15 and SY-17 calculated by MD simulations were -45.93 and -71.97 kcal/mol. MD simulations also revealed that both compounds act as bitopic agonists, occupying the orthosteric site and a novel exosite of the receptor simultaneously. Our findings of integrative computational and experimental approaches could offer the potential to enhance ligand affinity and selectivity through dual-site occupancy and provide a novel direction for the rational design of sedatives and analgesics.

Keywords: bitopic agonist; ensemble-based screening; molecular dynamics simulation; α2A-AR.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Chemical structures of α2A-AR agonists and antagonists.
Figure 2
Figure 2
(A) Workflow of ensemble-based screening strategy for novel α2A-AR agonists; (B) RMSD of protein backbone during MD simulation; (C) conformations of 10 clusters and crystal structures; (D) conformational differences of key binding site residues for 10 clusters.
Figure 3
Figure 3
Structure-based virtual screening for novel α2A-AR agonists. (A) Workflow of virtual screening in Chemdiv library; (B) LogP, molecular weight and PSA comparison of candidate compounds (pink) with known α2A-AR ligands (green); (C) docking scores of 20 molecules for each cluster.
Figure 4
Figure 4
Biological evaluation for candidate compounds based on PKA and cAMP assays. (A) Effect of 20 compounds in PKA redistribution assay; (B) preliminarily biological evaluation on cAMP assay in vitro for candidate compounds; (C) the dose–effect of SY-17 and SY-15 in regulating cAMP levels.
Figure 5
Figure 5
Chemical structures and binding modes of α2A-AR ligands. (A) Interactions between α2A-AR and DMED, with the imidazole ring binding to the orthosteric site with a slat bridge and hydrogen bond; (BD) binding mode of molecules SY-12, SY-15, and SY-17 with α2A-AR; (E) exosite and orthosteric site of α2A-AR.
Figure 6
Figure 6
MD simulation of SY-17 and α2A-AR complex. (A) RMSD plot of α2A-AR with ligand SY-17. The ligand was aligned to the protein and then calculated RMSD; (B) RMSF plot of α2A-AR, the green lines illustrated certain residues which contacted with ligand; (C) fraction of simulation time of specific residue interactions during 1000 ns simulation shown with L-P plot. The displayed residue interacted with the ligand for at least 10% of the simulation time; (D) interaction fractions of α2A-AR active residues with SY-17 (hydrogen bonds are shown with green bars; ionic and water bridges are shown with pink and blue color bars; hydrophobic are shown with purple); (E) plots of protein–ligand contacts and interactions during 1000 ns simulation.
Figure 7
Figure 7
(A) Decomposed binding free energy of SY-15 (residues located in the orthosteric site were colored blue, while in exosites were red); (B) binding free energy of SY-17.
Figure 8
Figure 8
(A) α-AR receptor family sequence conservation in orthosteric sites; (B) sequence conservation of exosites.

Similar articles

Cited by

References

    1. Pettinger W.A., Jackson E.K. α (2)-Adrenoceptors: Challenges and Opportunities-Enlightenment from the Kidney. Cardiovasc. Ther. 2020;2020:2478781. doi: 10.1155/2020/2478781. - DOI - PMC - PubMed
    1. Xu J., Cao S., Hübner H., Weikert D., Chen G., Lu Q., Yuan D., Gmeiner P., Liu Z., Du Y. Structural insights into ligand recognition, activation, and signaling of the α(2A) adrenergic receptor. Sci. Adv. 2022;8:eabj5347. doi: 10.1126/sciadv.abj5347. - DOI - PMC - PubMed
    1. Chhatar S., Lal G. Role of adrenergic receptor signalling in neuroimmune communication. Curr. Res. Immunol. 2021;2:202–217. doi: 10.1016/j.crimmu.2021.11.001. - DOI - PMC - PubMed
    1. Tsivitis A., Wang A., Murphy J., Khan A., Jin Z., Moore R., Tateosian V., Bergese S. Anesthesia, the developing brain, and dexmedetomidine for neuroprotection. Front. Neurol. 2023;14:1150135. doi: 10.3389/fneur.2023.1150135. - DOI - PMC - PubMed
    1. Schwinn D.A., Correa-Sales C., Page S.O., Maze M. Functional effects of activation of alpha-1 adrenoceptors by dexmedetomidine: In vivo and in vitro studies. J. Pharmacol. Exp. Ther. 1991;259:1147–1152. - PubMed